Solaxa
Bethesda, US · Founded 2021 · Delaware corporation · 2 known investors
Find your way into Solaxa
49 people in our graph share verified history with the Solaxa team — schools, employers, funds. One of them is your warm intro.
William Sheahanunlockedknows Mark Noble · together at University of Rochester Medical Center (overlapped)
×2knows the team · via UCL
×2knows the team · via University of Rochester Medical Center
×7knows the team · via Franklin & Marshall College
Solaxa is a biotech company developing pharmacological and cell-based treatments for peripheral nerve injury and spinal cord injury, drawing on regenerative medicine and nerve technologies. It focuses on drug and drug-device combination products in the field of neurology.
Founders & leadership
Solaxa was founded in 2021 by Mark Noble.
MN
Mark NobleinChief Science Officer & Co-FounderMark Noble holds academic positions in neurology and biomedical genetics at the University of Rochester School of Medicine and directs its Stem Cell and Regenerative Medicine Institute, with a Ph.D. from Stanford University. He has authored over 150 scientific publications and holds multiple patents in stem cell biology and regenerative medicine, and previously served on the scientific advisory board of Acorda Therapeutics.
CW
Christian WalkerinPresident, Chief Development Officer & Founder
BP
Bill PasserChief Financial Officer
BN
Brad NaviainChief Medical Officer
Board
LG
Luis GutierrezBoard director
LS
Lauren SabellaBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$1.9M disclosed across 4 rounds · 2021–2024
▶$305KraisedSep 2024 · 4 investors · PharmaceuticalsRule 506(b)
▶$305KraisedSep 2024 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Luis GutierrezDirector
- Lauren SabellaDirector
- Christian WalkerExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $305K
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$500KraisedMay 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$500KraisedMay 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lauren SabellaDirector
- Christian WalkerExecutive Officer, Director
- Luis GutierrrezExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$729KraisedMay 2024 · 13 investors · PharmaceuticalsRule 506(b)
▶$729KraisedMay 2024 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christian WalkerExecutive Officer, Director
- Lauren SabellaDirector
- Luis GutierrezExecutive Officer, Director
- Offering amount
- $729K
- Amount sold
- $729K
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$365KraisedMay 2024 · 8 investors · PharmaceuticalsRule 506(b)
▶$365KraisedMay 2024 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Luis GutierrezExecutive Officer, Director
- Christian WalkerExecutive Officer, Director
- Lauren SabellaDirector
- Offering amount
- $2.1M
- Amount sold
- $365K
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapCybrexa, Inc.11 shared keywordsCybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.
Exelixis7 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies competing with Solaxa for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Solaxa do?
- Solaxa is a biotech company developing pharmacological and cell-based treatments for peripheral nerve injury and spinal cord injury, drawing on regenerative medicine and nerve technologies. It focuses on drug and drug-device combination products in the field of neurology.
- Who founded Solaxa?
- Solaxa was founded by Mark Noble in 2021.
- Who are Solaxa's investors?
- Solaxa's investors include Maryland TEDCO, TEDCO.
- How much funding has Solaxa raised?
- Solaxa has disclosed $1.9M raised across 4 rounds.
- Where is Solaxa headquartered?
- Solaxa is headquartered in Bethesda, US.